Steven G DuBois

Summary

Affiliation: University of California
Country: USA

Publications

  1. ncbi request reprint 131I-Metaiodobenzylguanidine therapy in children with advanced neuroblastoma
    S G Dubois
    Department of Pediatrics, UCSF School of Medicine, San Francisco, CA, USA
    Q J Nucl Med Mol Imaging 57:53-65. 2013
  2. doi request reprint Phase I study of vincristine, irinotecan, and ¹³¹I-metaiodobenzylguanidine for patients with relapsed or refractory neuroblastoma: a new approaches to neuroblastoma therapy trial
    Steven G DuBois
    Department of Pediatrics, UCSF School of Medicine, San Francisco, California 94143, USA
    Clin Cancer Res 18:2679-86. 2012
  3. pmc Evaluation of polymorphisms in EWSR1 and risk of Ewing sarcoma: a report from the Childhood Cancer Survivor Study
    Steven G DuBois
    Department of Pediatrics, UCSF School of Medicine, San Francisco, California 94143 0106, USA
    Pediatr Blood Cancer 59:52-6. 2012
  4. doi request reprint Tolerability and pharmacokinetic profile of a sunitinib powder formulation in pediatric patients with refractory solid tumors: a Children's Oncology Group study
    Steven G DuBois
    Department of Pediatrics, UCSF School of Medicine, 505 Parnassus Avenue, M646, San Francisco, CA 94143 0106, USA
    Cancer Chemother Pharmacol 69:1021-7. 2012
  5. pmc Phase II study of intermediate-dose cytarabine in patients with relapsed or refractory Ewing sarcoma: a report from the Children's Oncology Group
    Steven G DuBois
    Department of Pediatrics, UCSF School of Medicine, San Francisco, California 94143 0106, USA
    Pediatr Blood Cancer 52:324-7. 2009
  6. pmc Circulating endothelial cells and circulating endothelial precursor cells in patients with osteosarcoma
    Steven G DuBois
    Department of Pediatrics, UCSF School of Medicine, San Francisco, CA, USA
    Pediatr Blood Cancer 58:181-4. 2012
  7. pmc Lung metastases in neuroblastoma at initial diagnosis: A report from the International Neuroblastoma Risk Group (INRG) project
    Steven G DuBois
    Department of Pediatrics, University of California, San Francisco, California, USA
    Pediatr Blood Cancer 51:589-92. 2008
  8. pmc Phase I and pharmacokinetic study of sunitinib in pediatric patients with refractory solid tumors: a children's oncology group study
    Steven G DuBois
    Department of Pediatrics, University of California, San Francisco School of Medicine, San Francisco, CA 94143 0106, USA
    Clin Cancer Res 17:5113-22. 2011
  9. pmc Angiogenesis and vascular targeting in Ewing sarcoma: a review of preclinical and clinical data
    Steven G DuBois
    Department of Pediatrics, University of California at San Francisco School of Medicine, San Francisco, California 94143 0106, USA
    Cancer 116:749-57. 2010
  10. doi request reprint Late recurrence of ewing sarcoma during pregnancy: a report of 2 cases
    Steven G DuBois
    Department of Pediatrics, University of California, San Francisco, CA 94143 0106, USA
    J Pediatr Hematol Oncol 30:716-8. 2008

Collaborators

Detail Information

Publications36

  1. ncbi request reprint 131I-Metaiodobenzylguanidine therapy in children with advanced neuroblastoma
    S G Dubois
    Department of Pediatrics, UCSF School of Medicine, San Francisco, CA, USA
    Q J Nucl Med Mol Imaging 57:53-65. 2013
    ..Given the documented activity of 131I-MIBG, future studies will need to evaluate the impact of radiation sensitizers on this activity and define the role of this agent in treating patients with newly diagnosed high-risk neuroblastoma...
  2. doi request reprint Phase I study of vincristine, irinotecan, and ¹³¹I-metaiodobenzylguanidine for patients with relapsed or refractory neuroblastoma: a new approaches to neuroblastoma therapy trial
    Steven G DuBois
    Department of Pediatrics, UCSF School of Medicine, San Francisco, California 94143, USA
    Clin Cancer Res 18:2679-86. 2012
    ..Irinotecan is a known radiosensitizer with activity in neuroblastoma. This phase I study aimed to determine the recommended phase 2 dose of MIBG together with fixed doses of vincristine and irinotecan...
  3. pmc Evaluation of polymorphisms in EWSR1 and risk of Ewing sarcoma: a report from the Childhood Cancer Survivor Study
    Steven G DuBois
    Department of Pediatrics, UCSF School of Medicine, San Francisco, California 94143 0106, USA
    Pediatr Blood Cancer 59:52-6. 2012
    ..Ewing sarcoma is a malignant bone tumor characterized by a high frequency of somatic EWSR1 translocations. Ewing sarcoma is less common in people of African or African-American ancestry, suggesting a genetic etiology...
  4. doi request reprint Tolerability and pharmacokinetic profile of a sunitinib powder formulation in pediatric patients with refractory solid tumors: a Children's Oncology Group study
    Steven G DuBois
    Department of Pediatrics, UCSF School of Medicine, 505 Parnassus Avenue, M646, San Francisco, CA 94143 0106, USA
    Cancer Chemother Pharmacol 69:1021-7. 2012
    ..A pediatric phase I study of sunitinib capsules identified the maximum tolerated dose as 15 mg/m(2)/day. This study was conducted to evaluate sunitinib given as a powder formulation...
  5. pmc Phase II study of intermediate-dose cytarabine in patients with relapsed or refractory Ewing sarcoma: a report from the Children's Oncology Group
    Steven G DuBois
    Department of Pediatrics, UCSF School of Medicine, San Francisco, California 94143 0106, USA
    Pediatr Blood Cancer 52:324-7. 2009
    ..The purpose of this phase II clinical trial was to estimate the response rate of intermediate-dose cytarabine in patients with relapsed or refractory Ewing sarcoma...
  6. pmc Circulating endothelial cells and circulating endothelial precursor cells in patients with osteosarcoma
    Steven G DuBois
    Department of Pediatrics, UCSF School of Medicine, San Francisco, CA, USA
    Pediatr Blood Cancer 58:181-4. 2012
    ..Circulating endothelial cells (CECs) have been detected at increased numbers in patients with solid cancers. CECs have not been systematically evaluated in patients with osteosarcoma...
  7. pmc Lung metastases in neuroblastoma at initial diagnosis: A report from the International Neuroblastoma Risk Group (INRG) project
    Steven G DuBois
    Department of Pediatrics, University of California, San Francisco, California, USA
    Pediatr Blood Cancer 51:589-92. 2008
    ..We aimed to describe the incidence, clinical characteristics, and outcome of patients with lung metastasis at initial diagnosis using a large international database...
  8. pmc Phase I and pharmacokinetic study of sunitinib in pediatric patients with refractory solid tumors: a children's oncology group study
    Steven G DuBois
    Department of Pediatrics, University of California, San Francisco School of Medicine, San Francisco, CA 94143 0106, USA
    Clin Cancer Res 17:5113-22. 2011
    ..The purpose of this study was to determine the recommended phase 2 dose, pharmacokinetics, pharmacodynamic effects, and preliminary antitumor activity of sunitinib in a pediatric population...
  9. pmc Angiogenesis and vascular targeting in Ewing sarcoma: a review of preclinical and clinical data
    Steven G DuBois
    Department of Pediatrics, University of California at San Francisco School of Medicine, San Francisco, California 94143 0106, USA
    Cancer 116:749-57. 2010
    ..For the current review, the authors summarized the available data supporting this approach...
  10. doi request reprint Late recurrence of ewing sarcoma during pregnancy: a report of 2 cases
    Steven G DuBois
    Department of Pediatrics, University of California, San Francisco, CA 94143 0106, USA
    J Pediatr Hematol Oncol 30:716-8. 2008
    ..These receptors were not detected by immunohistochemistry. Increased medical surveillance during pregnancy may have resulted in ascertainment of recurrence in these 2 patients...
  11. pmc Flow cytometric detection of Ewing sarcoma cells in peripheral blood and bone marrow
    Steven G DuBois
    Department of Pediatrics, University of California San Francisco School of Medicine, San Francisco, CA 94143 0106, USA
    Pediatr Blood Cancer 54:13-8. 2010
    ..A new method for detecting circulating Ewing sarcoma cells using flow cytometry is described. This strategy exploits the nearly universal expression of CD99 and the lack of expression of CD45 by Ewing sarcoma cells...
  12. doi request reprint Comparison of Latino and non-Latino patients with Ewing sarcoma
    Jeremy Sharib
    Department of Pediatrics, San Francisco School of Medicine, University of California, San Francisco, California Department of Pathology, San Francisco School of Medicine, University of California, San Francisco, California
    Pediatr Blood Cancer 61:233-7. 2014
    ....
  13. doi request reprint Dose escalation study of no-carrier-added 131I-metaiodobenzylguanidine for relapsed or refractory neuroblastoma: new approaches to neuroblastoma therapy consortium trial
    Katherine K Matthay
    Department of Pediatrics, UCSF School of Medicine, San Francisco, CA, USA
    J Nucl Med 53:1155-63. 2012
    ..Our aim was to establish the maximum tolerated dose of no-carrier-added (NCA) (131)I-MIBG, with secondary aims of assessing tumor and organ dosimetry and overall response...
  14. doi request reprint Adverse impact of regional lymph node involvement in osteosarcoma
    Sheila Thampi
    Department of Pediatrics, University of California, San Francisco School of Medicine, 505 Parnassus Ave, San Francisco, CA 94143, United States
    Eur J Cancer 49:3471-6. 2013
    ..We investigated incidence, patient characteristics and survival for patients with osteosarcoma and regional lymph node involvement at diagnosis...
  15. pmc Predictors of acute chemotherapy-associated toxicity in patients with Ewing sarcoma
    Jeremy M Sharib
    Department of Pediatrics, University of California, San Francisco School of Medicine, San Francisco, California 94143 0106, USA
    Pediatr Blood Cancer 59:611-6. 2012
    ..Patients with ES are treated with intensive chemotherapy regimens. We describe predictors of acute chemotherapy-associated toxicity in this population...
  16. pmc Cooperation of the HDAC inhibitor vorinostat and radiation in metastatic neuroblastoma: efficacy and underlying mechanisms
    Sabine Mueller
    Department of Neurology, University of California, San Francisco, 505 Parnassus Avenue, San Francisco, CA 94143 0106, USA
    Cancer Lett 306:223-9. 2011
    ..DNA repair enzyme Ku-86 was reduced in several neuroblastoma cells treated with vorinostat. Thus, vorinostat potentiates anti-neoplastic effects of radiation in neuroblastoma possibly due to down-regulation of DNA repair enzyme Ku-86...
  17. pmc Prognostic value of the stage 4S metastatic pattern and tumor biology in patients with metastatic neuroblastoma diagnosed between birth and 18 months of age
    Denah R Taggart
    UCSF School of Medicine and Benioff Children s Hospital, San Francisco, CA 94143 0106, USA
    J Clin Oncol 29:4358-64. 2011
    ..Our aim was to determine which prognostic features could be used for optimal risk classification among patients younger than 18 months with metastatic disease...
  18. pmc Characteristics and outcomes of patients with Ewing sarcoma over 40 years of age at diagnosis
    Erin E Karski
    Department of Pediatrics, UCSF School of Medicine, San Francisco, CA 94143 0106, USA
    Cancer Epidemiol 37:29-33. 2013
    ..The peak incidence of Ewing sarcoma (EWS) is in adolescence, with little known about patients who are ≥40 years at diagnosis. We describe the clinical characteristics and survival of this rare group...
  19. ncbi request reprint Hematologic toxicity of high-dose iodine-131-metaiodobenzylguanidine therapy for advanced neuroblastoma
    Steven G DuBois
    Department of Pediatrics, University of California, San Francisco, San Francisco, CA 94143, USA
    J Clin Oncol 22:2452-60. 2004
    ..The goal of this study was to determine risk factors for myelosuppression and the need for AHSCT after (131)I-MIBG treatment...
  20. doi request reprint 131I-MIBG followed by consolidation with busulfan, melphalan and autologous stem cell transplantation for refractory neuroblastoma
    Sarah French
    Department of Pediatrics, University of California, San Francisco School of Medicine, San Francisco, California 94143, USA
    Pediatr Blood Cancer 60:879-84. 2013
    ..The purpose of our report was to evaluate safety and response with MIBG therapy followed by myeloablative busulfan and melphalan (BuMel) with ASCT in patients with refractory neuroblastoma...
  21. pmc Racial differences in the incidence of mesenchymal tumors associated with EWSR1 translocation
    Jennifer Worch
    Department of Pediatrics, University of California, San Francisco, School of Medicine, 505 Parnassus Avenue, M646, San Francisco, CA 94143 0106, USA
    Cancer Epidemiol Biomarkers Prev 20:449-53. 2011
    ..The incidence of Ewing sarcoma varies by race, with very low rates among persons of African and East Asian ancestry. The incidence by race of other mesenchymal tumors that also harbor EWSR1 translocations has not been studied...
  22. pmc Clinical features and outcomes in patients with Ewing sarcoma and regional lymph node involvement
    Mark A Applebaum
    Department of Pediatrics, School of Medicine, University of California, San Francisco, California 94143 0106, USA
    Pediatr Blood Cancer 59:617-20. 2012
    ..A minority of patients with Ewing sarcoma present with regional lymph node involvement. We investigated if patient characteristics and outcomes differ between patients with Ewing sarcoma with and without regional node involvement...
  23. pmc Osteosarcoma in children 5 years of age or younger at initial diagnosis
    Jennifer Worch
    Department of Pediatrics and Department of Epidemiology Biostatistics, University of California, San Francisco School of Medicine, San Francisco, California, USA
    Pediatr Blood Cancer 55:285-9. 2010
    ..Since osteosarcoma is extremely rare in children < or =5 years of age, we sought to investigate if tumor characteristics, treatment strategies, and outcomes differ compared to older patients...
  24. pmc Clinical features and outcomes in patients with extraskeletal Ewing sarcoma
    Mark A Applebaum
    Department of Pediatrics, University of California, San Francisco School of Medicine, San Francisco, California, USA
    Cancer 117:3027-32. 2011
    ..The purpose of this study was to investigate whether patient characteristics, treatment strategies, and outcomes differ between skeletal Ewing sarcoma and extraskeletal Ewing sarcoma (EES)...
  25. pmc Response, survival, and toxicity after iodine-131-metaiodobenzylguanidine therapy for neuroblastoma in preadolescents, adolescents, and adults
    Alexei L Polishchuk
    Department of Pediatrics, University of California at San Francisco School of Medicine and UCSF Benioff Children s Hospital, San Francisco, California, USA
    Cancer 117:4286-93. 2011
    ..The objective of the current study was to characterize the toxicity and activity of this therapy in older patients...
  26. pmc Clinical features and outcomes in patients with secondary Ewing sarcoma
    Mark A Applebaum
    Department of Pediatrics, University of California, San Francisco School of Medicine, San Francisco, California 94143 0106, USA
    Pediatr Blood Cancer 60:611-5. 2013
    ..Ewing sarcoma (EWS) is rarely diagnosed as a second malignancy. We sought to describe a cohort of patients with secondary EWS and investigate if patient characteristics and survival differ between patients with secondary and primary EWS...
  27. pmc Radiolabeled metaiodobenzylguanidine for the treatment of neuroblastoma
    Steven G DuBois
    Department of Pediatrics, UCSF School of Medicine, Box 0106, San Francisco, CA 94143 0106, USA
    Nucl Med Biol 35:S35-48. 2008
    ..Neuroblastoma is the most common pediatric extracranial solid cancer. This tumor is characterized by metaiodobenzylguanidine (MIBG) avidity in 90% of cases, prompting the use of radiolabeled MIBG for targeted radiotherapy in these tumors...
  28. doi request reprint Acute changes in blood pressure in patients with neuroblastoma treated with ¹³¹I-metaiodobenzylguanidine (MIBG)
    Thalia Wong
    Department of Pediatrics, University of California, San Francisco School of Medicine, San Francisco, California 94143 0106, USA
    Pediatr Blood Cancer 60:1424-30. 2013
    ..The aim of our study was to evaluate systematically the acute effects of (131)I-MIBG on blood pressure in patients with neuroblastoma and to identify possible predictors of hypertension...
  29. doi request reprint Chemotherapy: The role of ifosfamide and etoposide in Ewing sarcoma
    Steven G DuBois
    University of California San Francisco UCSF School of Medicine, San Francisco, CA, USA
    Nat Rev Clin Oncol 6:251-3. 2009
    ..Subgroup analysis suggested that patients with large, localized tumors benefited from the addition of etoposide, whereas patients with metastases did not...
  30. doi request reprint Successful treatment of high risk and recurrent pediatric desmoids using radiation as a component of multimodality therapy
    Siavash Jabbari
    Department of Radiation Oncology, University of California, San Francisco, CA, USA
    Int J Radiat Oncol Biol Phys 75:177-82. 2009
    ..To evaluate the role of radiation therapy (RT) as a component of multimodality therapy for pediatric desmoids...
  31. pmc Evaluation of Norepinephrine Transporter Expression and Metaiodobenzylguanidine Avidity in Neuroblastoma: A Report from the Children's Oncology Group
    Steven G DuBois
    Department of Pediatrics, UCSF School of Medicine, 505 Parnassus Avenue, M696, San Francisco, CA 94143 0106, USA
    Int J Mol Imaging 2012:250834. 2012
    ..0002). Conclusions. NET protein expression in neuroblastoma correlates with MIBG avidity. MYCN amplified tumors have lower NET protein expression...
  32. pmc Ethnic and racial differences in patients with Ewing sarcoma
    Jennifer Worch
    Department of Pediatrics, University of California at San Francisco School of Medicine, 505 Parnassus Avenue, M646, San Francisco, CA 94143 0106, USA
    Cancer 116:983-8. 2010
    ..The goal of the current study was to evaluate racial and ethnic differences in presentation and overall survival (OS) among patients diagnosed with ES before age 40 years...
  33. doi request reprint Current treatment and outcome for childhood acute leukemia in Tanzania
    Elizabeth Kersten
    Department of Pediatrics, University of California San Francisco School of Medicine and UCSF Benioff Children s Hospital, San Francisco, California
    Pediatr Blood Cancer 60:2047-53. 2013
    ....
  34. pmc Development of anaplastic Wilms tumor and subsequent relapse in a child with diaphanospondylodysostosis
    Sarah K Tasian
    Department of Pediatrics, Division of Pediatric Hematology Oncology, University of California, San Francisco School of Medicine, San Francisco, CA, USA
    J Pediatr Hematol Oncol 34:548-51. 2012
    ..We describe a patient with DSD who developed bilateral hyperplastic nephroblastomatosis that ultimately evolved into therapy-resistant anaplastic Wilms tumor (nephroblastoma)...
  35. pmc Vorinostat increases expression of functional norepinephrine transporter in neuroblastoma in vitro and in vivo model systems
    Swati S More
    Departments of Bioengineering and Therapeutic Sciences, UCSF School of Medicine and UCSF Benioff Children s Hospital, San Francisco, California 94158, USA
    Clin Cancer Res 17:2339-49. 2011
    ....
  36. pmc Superselective intra-arterial melphalan therapy for newly diagnosed and refractory retinoblastoma: results from a single institution
    Sheila Thampi
    Department of Pediatrics, University of California, San Francisco School of Medicine, San Francisco, CA, USA
    Clin Ophthalmol 7:981-9. 2013
    ..This report describes our results using superselective intra-arterial melphalan in patients with newly diagnosed retinoblastoma and those who were treated for progression after systemic chemotherapy...